Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Silexion Therapeutics (NASDAQ: SLXN) entered definitive agreements for the immediate cash exercise of certain outstanding warrants to purchase up to 1,995,092 ordinary shares at $0.50 per share, for expected gross proceeds of about $1 million before fees.

Rhea-AI Summary

Silexion Therapeutics (NASDAQ: SLXN) entered definitive agreements for the immediate cash exercise of certain outstanding warrants to purchase up to 1,995,092 ordinary shares at $0.50 per share, for expected gross proceeds of about $1 million before fees.

The company plans to use net proceeds as working capital for general corporate purposes. In connection, Silexion will issue new unregistered Series C warrants for up to 2,045,000 shares and Series D warrants for up to 1,945,184 shares, each with a $0.50 exercise price and expirations of five years and twenty-four months, respectively, after specified shareholder approval and resale registration milestones.

Positive

• Approximately $1 million gross proceeds from warrant exercises at $0.50 per share
• Cash earmarked as working capital for general corporate purposes
• Immediate exercise of certain outstanding warrants provides near-term funding

Negative

• Issuance of up to 1,995,092 new shares creates shareholder dilution
• New Series C and D warrants for up to 3,990,184 shares add future dilution overhang
• Placement agent fees and offering expenses reduce net cash proceeds
• Exercise of new warrants depends on shareholder approval and registration effectiveness

Argus May 15 session

-42.06% close to close Open Argus

Details

News Market Reaction – SLXN

On May 15, the day this news came out, SLXN closed 42.06% below the previous close.

Data tracked by StockTitan Argus for the May 15 session.

Market Context

On May 15, the day this news came out, the stock closed 42.1% below the previous close. A negative r...

Analysis

On May 15, the day this news came out, the stock closed 42.1% below the previous close. A negative reaction despite modest gross proceeds aligns with SLXN’s history, where financing news averaged about -25.6%. The deal adds 1,995,092 exercised shares plus nearly 4 million new Series C and D warrants at $0.50, reinforcing dilution concerns. An existing shelf that could bring in up to $4.9M via warrant exercises underscores ongoing equity overhang, so future sentiment may hinge on execution in SIL204’s Phase 2/3 program.

Key Figures

Shares under exercised warrants: 1,995,092 shares Exercise price: $0.50 per share Gross proceeds: approximately $1 million +5 more

Shares under exercised warrants

1,995,092 shares

Immediate exercise of outstanding warrants originally issued Aug/Sep 2025

Exercise price

$0.50 per share

Reduced exercise price for immediately exercised warrants

Gross proceeds

approximately $1 million

Expected gross proceeds before fees and expenses

Series C new warrants

2,045,000 warrants

New unregistered Series C warrants issued to investors

Series D new warrants

1,945,184 warrants

New unregistered Series D warrants issued to investors

New warrant exercise price

$0.50 per share

Exercise price for both Series C and Series D new warrants

Series C term

five years

Expiration after later of shareholder approval and resale registration effectiveness

Series D term

twenty-four months

Expiration after later of shareholder approval and resale registration effectiveness

Previous Offering Reports

4 past events · Latest: Sep 11

Same Type 4 events

1. Sep 11

   $6M public offering

   24h Move

   +9.9%

   Pricing of $6.0M public equity and warrant offering at $4.00 per share.

2. Jul 31

   Warrants exercised

   24h Move

   -37.9%

   Exercise of warrants for $1.8M gross proceeds with new 24-month warrants.

3. Jan 29

   Warrant exercise deal

   24h Move

   -34.7%

   Immediate warrant exercise generating ~$3.3M and issuance of new 24‑month warrants.

4. Jan 15

   $5M public offering

   24h Move

   -39.7%

   Pricing of $5.0M offering of shares plus 5‑year warrants at $1.35.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

warrants, registration statement on form s-3, resale registration statement, private placement, +2 more

6 terms

warrants financial

"announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

registration statement on form s-3 regulatory

"registered pursuant to an effective registration statement on Form S-3 (File No. 333-290074)"

A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.

resale registration statement regulatory

"an effective resale registration statement on Form S-3 (No. 333-291210)"

A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.

private placement financial

"The new warrants described above were offered in a private placement pursuant to an applicable exemption"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

placement agent financial

"H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering"

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

resale registration statement regulatory

"file a registration statement with the SEC covering the resale of the ordinary shares issuable"

A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,995,092 of the Company’s ordinary shares originally issued in August 2025 and September 2025 having a reduced exercise price of $0.50 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-290074) and an effective resale registration statement on Form S-3 (No. 333-291210). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about May 18, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series C warrants to purchase up to 2,045,000 of the Company’s ordinary shares and new unregistered Series D warrants to purchase up to 1,945,184 of the Company’s ordinary shares. The new warrants will have an exercise price of $0.50 per share and will be exercisable upon the effective date of shareholder approval of the issuance of the ordinary shares issuable upon exercise of the new warrants. The Series C new warrants will expire five years after the later of (i) the date of shareholder approval and (ii) the effective date of the Resale Registration Statement (as defined below) and the Series D new warrants will expire twenty-four months after the later of (x) the date of shareholder approval and (y) the effective date of the Resale Registration Statement.

The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the “Resale Registration Statement”).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product, which showed a positive trend in comparison to the control of chemotherapy alone, and is currently advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), towards clinical trials in Israel and the European Union. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the receipt of shareholder approval and the intended use of net proceeds from the offering, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion’s ability to successfully complete preclinical studies and initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities, including the outcome of the CTA’s review of the Company’s application to commence clinical trials in Germany and other jurisdictions, as well as site-level approvals, conditions and clearances (including outstanding regulatory forms and any initial participant caps) required prior to study commencement at each clinical site; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion’s ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Relations Contact
Arx Investor Relation
North American Equities Desk
silexion@arxhq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Silexion Therapeutics (NASDAQ: SLXN) announce on May 15, 2026?

Silexion announced agreements for the immediate exercise of certain outstanding warrants, expected to raise about $1 million in gross proceeds. According to Silexion, the exercised warrants cover up to 1,995,092 ordinary shares at an exercise price of $0.50 per share.

How much capital will Silexion Therapeutics (SLXN) raise from the warrant exercise?

Silexion expects gross proceeds of approximately $1 million from the warrant exercises. According to Silexion, these proceeds come from the cash exercise of warrants to buy up to 1,995,092 ordinary shares at an exercise price of $0.50 per share.

How will Silexion Therapeutics use the proceeds from the $1 million warrant exercise?

Silexion plans to use the net proceeds as working capital for general corporate purposes. According to Silexion, this capital raise supports ongoing operations while it develops RNA interference therapies targeting KRAS-driven cancers in its clinical-stage pipeline.

What are the terms of Silexion Therapeutics’ new Series C and Series D warrants?

Silexion will issue new unregistered Series C warrants for up to 2,045,000 shares and Series D warrants for up to 1,945,184 shares. According to Silexion, both carry a $0.50 exercise price and become exercisable after shareholder approval and effectiveness of a resale registration statement.

When is the Silexion Therapeutics (SLXN) warrant exercise financing expected to close?

The financing is expected to close on or about May 18, 2026, subject to customary closing conditions. According to Silexion, H.C. Wainwright & Co. is acting as the exclusive placement agent for this warrant exercise transaction.

What potential dilution could Silexion Therapeutics shareholders face from the new warrants?

Shareholders may face dilution from ordinary shares issued upon exercise of existing and new warrants. According to Silexion, up to 1,995,092 shares will be issued now, with additional potential issuances from 2,045,000 Series C and 1,945,184 Series D warrants at $0.50 per share.